Jiangxi Synergy Pharmaceutical is an API manufacturer based in China. It holds 20 active US drug master files across a filed portfolio of 20 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 7 August 2025 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3008465739 |
| Molecule | Regulators | Docs |
|---|---|---|
| Gabapentin | SFDA (Saudi Arabia), US FDA | 4 |
| Celecoxib | SFDA (Saudi Arabia), US FDA | 3 |
| Azilsartan Medoxomil | US FDA | 2 |
| Edoxaban | SFDA (Saudi Arabia), US FDA | 2 |
| Empagliflozin | SFDA (Saudi Arabia), US FDA | 2 |
| Vildagliptin | SFDA (Saudi Arabia), US FDA | 2 |
| Vonoprazan | SFDA (Saudi Arabia), US FDA | 2 |
| Apixaban | US FDA | 1 |
| Canagliflozin | US FDA | 1 |
| Crisaborole | US FDA | 1 |
| Dabigatran Etexilate | US FDA | 1 |
| Dapagliflozin | US FDA | 1 |
| Febuxostat | US FDA | 1 |
| Mirabegron | US FDA | 1 |
| Mirabegron Α | SFDA (Saudi Arabia) | 1 |
| Opicapone | US FDA | 1 |
| Rabeprazole | SFDA (Saudi Arabia) | 1 |
| Rivaroxaban | US FDA | 1 |
| Roxadustat | US FDA | 1 |
| Ticagrelor | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 4 | None |
| US FDA | None | 1 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Ask Fred what the record holds on Jiangxi Synergy Pharmaceutical, including filings and inspection history.
Chat with Fred, your AI analystRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.